Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2

Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2

Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic innervations in central nervous system that resu...

Full description

Bibliographic Details
Main Authors:	O A Gerasimenko, E Pigarova, L K Dzeranova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2011-12-01
Series:	Ожирение и метаболизм
Subjects:	bromocriptine diabetes mellitus type 2 insulin dopamine
Online Access:	https://www.omet-endojournals.ru/jour/article/view/5298

Similar Items

Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review
by: Mulualem Tesfaye Birhan, et al.
Published: (2023-07-01)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
by: Via MA
Published: (2010-03-01)

Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects
by: Anthony H. Cincotta
Published: (2023-08-01)

Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet
by: Michael Ezrokhi, et al.
Published: (2021-06-01)

A Case Report of Trigeminal Neuralgia after Taking Bromocriptine
by: Reza Bavarsad Shahripour
Published: (2011-07-01)

A peripartum cardiomyopathy case treated with bromocriptine
by: Dilek Yeşilbursa, et al.
Published: (2021-03-01)

Serum prolactin level in chronic urticaria: Is bromocriptine inducing remission in chronic urticaria?
by: Mohamed Soliman, et al.
Published: (2018-11-01)

EFFECT OF OXYTOCIN AND BROMOCRIPTINE ON CORPORA LUTEA AND PSEUDOPREGNANCY IN MICE
by: N. A. S. AL- Khadi, et al.
Published: (1990-12-01)

Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature
by: Eng-Loon Tng, et al.
Published: (2023-03-01)

The Effect of Bromocriptine on the Disease Activity Index in Patients with Rheumatoid Arthritis
by: Mansour Salesi, et al.
Published: (2011-06-01)

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects
by: Anthony H. Cincotta, et al.
Published: (2022-08-01)

The regulatory effect of bromocriptine on cardiac hypertrophy by prolactin and D2 receptor modulation
by: Karla Aidee Aguayo-Cerón, et al.
Published: (2020-10-01)

Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
by: Lijuan Bai, et al.
Published: (2023-08-01)

Effectivity of Bromocriptine Administration Towards Prolactin Positive Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Literature Review
by: Muhammad Yadi Permana, et al.
Published: (2023-10-01)

Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction
by: Francesca Chiara Pignalosa, et al.
Published: (2021-11-01)

Insulin Fact Sheet in Type 1 and 2 Diabetes Mellitus and Trends of Antidiabetic Medication Use in Insulin Users with Type 2 Diabetes Mellitus: 2002 to 2019
by: Jiyun Park, et al.
Published: (2023-03-01)

Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
by: Tatiana Ivanovna Romantsova, et al.
Published: (2013-03-01)

Insulin adherence in adolescents with type 1 diabetes mellitus
by: Heena Dabas, et al.
Published: (2023-01-01)

Diabetes mellitus associated with type A insulin resistance
by: E. A. Sechko, et al.
Published: (2023-07-01)

Cutaneous manifestations in children patients with type 1 diabetes mellitus
by: Münevver Güven, et al.
Published: (2021-03-01)

Humalog Mix 25 in the treatment of type 2 diabetes mellitus
by: Vladimir Ivanovich Zoloedov, et al.
Published: (2012-06-01)

The relationship of vitamin D status with the development and course of diabetes mellitus type 1
by: Alexandra A. Povaliaeva, et al.
Published: (2020-06-01)

Association of Serum Ferritin with Risk of Anemia in Non-Diabetic Adolescents with Family History of Type 2 Diabetes Mellitus
by: Maira Mahmood, et al.
Published: (2021-12-01)

The Effects of Four Compounds That Act on the Dopaminergic and Serotonergic Systems on Working Memory in Animal Studies; A Literature Review
by: Ștefania-Alexandra Grosu, et al.
Published: (2023-03-01)

Progress on the pathogenesis of cardiovascular complications in patients with type 2 diabetes mellitus
by: ZHENG Tian-sheng, TONG Xue-wei, ZHANG Yi-tong, ZHU Min, ZHAN Xiao-rong
Published: (2022-05-01)

Frequency of Depression in Patients of Type 2 Diabetes Mellitus
by: Muhammad Ahsan Sana, et al.
Published: (2022-12-01)

Resistin , Insulin resistance and BMI in type 2 diabetes mellitus and healthy subjects.
by: Zainab A. Al-Shamma, et al.
Published: (2008-10-01)

Localized Insulin-Derived Amyloidosis in Diabetes Mellitus Type 1 Patient: A Case Report
by: Jan Hrudka, et al.
Published: (2023-07-01)

Individual stepwise intensification of insulin analogue therapy in type 2 diabetes mellitus
by: Alexander Sergeevich Ametov, et al.
Published: (2012-12-01)

Chemerin as a New Marker in Iraqi Newly Diagnosed Type 2 Diabetes Mellitus
by: Hind Shakir Ahmed, et al.
Published: (2015-06-01)

The experience with the use of insulin pump therapy in children and adolescents with type 1 diabetes mellitus
by: Nina Viktorovna Bolotova, et al.
Published: (2010-12-01)

Genetic framework of type 2 diabetes mellitus
by: Irina Arkad'evna Bondar', et al.
Published: (2013-12-01)

Relationship between insulin treatment and diabetic retinopathy in patients with type 2 diabetes mellitus
by: Jiao Su, et al.
Published: (2019-03-01)

Optimization of Bromocriptine-Mesylate-Loaded Polycaprolactone Nanoparticles Coated with Chitosan for Nose-to-Brain Delivery: In Vitro and In Vivo Studies
by: Mohamed M. Badran, et al.
Published: (2023-09-01)

Testosterone Levels with Insulin Resistance in Type 2 Diabetes Mellitus in Men
by: Mehnaz Khattak , Tariq Mahmood Ahmad , Jawwad Anis Khan , Asma Hayat
Published: (2016-12-01)

Cutaneous complications of insulin therapy in patients with Type1 diabetes mellitus
by: Munib A. Alzubaidi
Published: (2010-01-01)

Pathophysiology of Type 2 Diabetes Mellitus
by: Unai Galicia-Garcia, et al.
Published: (2020-08-01)

Uterine Arteries Resistance in Pregnant Women with Gestational Diabetes Mellitus, Diabetes Mellitus Type 1, Diabetes Mellitus Type 2, and Uncomplicated Pregnancies
by: Christos Chatzakis, et al.
Published: (2023-11-01)

Novel approach to pathophysiology of type 2 diabetes mellitus
by: Emil' Kopeevich Mukhamedzhanov, et al.
Published: (2013-12-01)

Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
by: Liu D, et al.
Published: (2021-04-01)